MedTrace Logo

Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy

NCT06557239 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-05-16

No results posted yet for this study

Summary

The main objective of this pilot study is to obtain preliminary data on the reactivity of salivary oxytocin during a single LSD intake as part of PAP treatment for anxiety disorders or depression (treatment authorisations granted in advance by the Federal Officie of Public Health for compassionate use of the substance).

There will be no interference with the usual clinical routine in our Service. The protocol is only for taking additional saliva measurements to measure oxytocin levels on the day of treatment.

Participants will be asked to give 4 saliva samples the day of their LSD treatment .In addition they will fill-in self-report questionnaires which are part of the clinical routine

Conditions

  • Depression, Anxiety

Interventions

DRUG

Lysergic Acid Diethylamide (LSD)

one single dose of LSD in the context of psychedelic assisted psychotherapy as a part of a clinical routine in our department

Sponsors & Collaborators

  • Tatiana Aboulafia Brakha

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2024-12-11
Completion
2024-12-11

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06557239 on ClinicalTrials.gov